Literature DB >> 20560005

Role of animal models in HCM research.

Rhian Shephard1, Christopher Semsarian.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a complex cardiovascular genetic disorder characterized by marked clinical and genetic heterogeneity. Major advances have been made in the clinical characterization of patients with HCM and in identifying causative gene mutations. However, many questions remain regarding the underlying disease mechanisms. Furthermore, in a disease where no pharmacological treatments currently exists which can either prevent or cause regression of disease, processes to identify novel therapies are the crucial next steps. Animal models of HCM have already proved to be universally useful in confirming gene causation and dissecting out key molecular pathways involved in the development of HCM and its sequelae, including heart failure and sudden death. These findings have led to studies in animal models investigating novel therapeutic approaches in HCM, specifically targeting the development and progression of cardiac hypertrophy, fibrosis, and heart failure. This review will provide a brief summary of some of the key animal models of HCM and how these models have been utilized to understand disease mechanisms and to investigate new potential therapies. Ongoing studies using animal models of HCM will lead to a greater understanding of disease pathogenesis and will facilitate the translation of these findings to improved clinical outcomes in HCM patients.

Entities:  

Mesh:

Year:  2009        PMID: 20560005     DOI: 10.1007/s12265-009-9120-y

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  66 in total

1.  Sarcomeric genotyping in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Steve R Ommen; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  Mayo Clin Proc       Date:  2005-04       Impact factor: 7.616

2.  Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice.

Authors:  Samantha P Harris; Christopher R Bartley; Timothy A Hacker; Kerry S McDonald; Pamela S Douglas; Marion L Greaser; Patricia A Powers; Richard L Moss
Journal:  Circ Res       Date:  2002-03-22       Impact factor: 17.367

3.  Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice.

Authors:  B K McConnell; K A Jones; D Fatkin; L H Arroyo; R T Lee; O Aristizabal; D H Turnbull; D Georgakopoulos; D Kass; M Bond; H Niimura; F J Schoen; D Conner; D A Fischman; C E Seidman; J G Seidman; D H Fischman
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

4.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.

Authors:  H Watkins; A Rosenzweig; D S Hwang; T Levi; W McKenna; C E Seidman; J G Seidman
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

5.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.

Authors:  Christopher Semsarian; Imran Ahmad; Michael Giewat; Dimitrios Georgakopoulos; Joachim P Schmitt; Bradley K McConnell; Steven Reiken; Ulrike Mende; Andrew R Marks; David A Kass; Christine E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

6.  A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy.

Authors:  C Semsarian; M J Healey; D Fatkin; M Giewat; C Duffy; C E Seidman; J G Seidman
Journal:  J Mol Cell Cardiol       Date:  2001-11       Impact factor: 5.000

7.  Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy.

Authors:  M J Tyska; E Hayes; M Giewat; C E Seidman; J G Seidman; D M Warshaw
Journal:  Circ Res       Date:  2000-04-14       Impact factor: 17.367

8.  Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  Sherif F Nagueh; Suetnee Chen; Rajnikant Patel; Natalia Tsybouleva; Silvia Lutucuta; Helen A Kopelen; William A Zoghbi; Miguel A Quiñones; Robert Roberts; A J Marian
Journal:  J Mol Cell Cardiol       Date:  2004-05       Impact factor: 5.000

9.  HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.

Authors:  J Bauersachs; S Störk; M Kung; C Waller; F Fidler; C Hoyer; S Frantz; F Weidemann; G Ertl; C E Angermann
Journal:  Eur J Clin Invest       Date:  2007-11       Impact factor: 4.686

Review 10.  Familial hypertrophic cardiomyopathy: from mutations to functional defects.

Authors:  G Bonne; L Carrier; P Richard; B Hainque; K Schwartz
Journal:  Circ Res       Date:  1998-09-21       Impact factor: 17.367

View more
  9 in total

1.  Ultrasonic Cavitation-Enabled Treatment for Therapy of Hypertrophic Cardiomyopathy: Proof of Principle.

Authors:  Douglas L Miller; Xiaofang Lu; Chunyan Dou; Yiying I Zhu; Rachael Fuller; Kristina Fields; Mario L Fabiilli; Gabe E Owens; David Gordon; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2018-04-19       Impact factor: 2.998

Review 2.  Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history.

Authors:  Christine E Seidman; J G Seidman
Journal:  Circ Res       Date:  2011-03-18       Impact factor: 17.367

3.  Myosin-binding protein C DNA variants in domestic cats (A31P, A74T, R820W) and their association with hypertrophic cardiomyopathy.

Authors:  M Longeri; P Ferrari; P Knafelz; A Mezzelani; A Marabotti; L Milanesi; G Pertica; M Polli; P G Brambilla; M Kittleson; L A Lyons; F Porciello
Journal:  J Vet Intern Med       Date:  2013-01-17       Impact factor: 3.333

4.  Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure.

Authors:  Richard D Bagnall; Tatiana Tsoutsman; Rhian E Shephard; William Ritchie; Christopher Semsarian
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

Review 5.  Molecular genetics made simple.

Authors:  Heba Sh Kassem; Francesca Girolami; Despina Sanoudou
Journal:  Glob Cardiol Sci Pract       Date:  2012-07-04

6.  Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy.

Authors:  Timothy J Cashman; Rebecca Josowitz; Bryce V Johnson; Bruce D Gelb; Kevin D Costa
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

7.  Disruption of embryonic ROCK signaling reproduces the sarcomeric phenotype of hypertrophic cardiomyopathy.

Authors:  Kate E Bailey; Guy A MacGowan; Simon Tual-Chalot; Lauren Phillips; Timothy J Mohun; Deborah J Henderson; Helen M Arthur; Simon D Bamforth; Helen M Phillips
Journal:  JCI Insight       Date:  2019-03-05

8.  Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities.

Authors:  Daniel P Judge; Hany Neamatalla; Russell A Norris; Robert A Levine; Jonathan T Butcher; Nicolas Vignier; Kevin H Kang; Quangtung Nguyen; Patrick Bruneval; Marie-Cécile Perier; Emmanuel Messas; Xavier Jeunemaitre; Annemarieke de Vlaming; Roger Markwald; Lucie Carrier; Albert A Hagège
Journal:  J Cardiovasc Dev Dis       Date:  2015-04-21

9.  Altered intercellular communication and extracellular matrix signaling as a potential disease mechanism in human hypertrophic cardiomyopathy.

Authors:  Amy Larson; Christina J Codden; Gordon S Huggins; Hassan Rastegar; Frederick Y Chen; Barry J Maron; Ethan J Rowin; Martin S Maron; Michael T Chin
Journal:  Sci Rep       Date:  2022-03-25       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.